Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III bempedoic acid in statin-insufficient hyperlipidemia
ChiCTR2600125607Phase 3Not yet recruiting
- Sponsor
- First Affiliated Hospital of Xi'an Jiaotong University
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hyperlipidemia, atherosclerotic disease and familial hypercholesterolemia (FH) comparing Bempedoic acid with Placebo (2 arms). Primary endpoint: Percentage change in LDL-C from baseline at 12 weeks of treatment. Planned start May 2026; status: not yet recruiting.
02
Drugs
bempedoic acid
03
Conditions
hyperlipidemiaatherosclerotic diseasefamilial hypercholesterolemia (FH)
Beyond the preview
Go deeper on ChiCTR2600125607.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600125607.